Orchid Pharma Limited — Results, 12-02-2025: Integrated Filing- Financial

Orchid Pharma has announced a board meeting where the directors approved the unaudited financial results for the quarter and half-year ended December 31, 2024, alongside the limited review reports from their auditors, Singhi & Co. The company reported no defaults on loans, with total indebtedness standing at ₹73.44 crore. This update reflects a stable financial position and compliance with disclosure norms. Investors may view this as a positive outlook, given the absence of defaults and timely reporting, indicating operational management clarity and financial health.